PDF DatasheetMouse Anti-CD357 / GITR / TNFRSF18 Antibody Product Attributes
CD357 / GITR / TNFRSF18 Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD357 / GITR / TNFRSF18 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. Low, but measureable presence of CD357 / GITR / TNFRSF18 could be seen inhematopoietic cells in the bone marrow, glandular cells in the breast, colon and gallbladder, pneumocytes in lung, germinal center cells in the lymph node, respiratory epithelial cells in the nasopharynx, exocrine glandular cells in the pancreas, glandular cells in the parathyroid gland and rectum, keratinocytes in skin, cells in the red pulp in spleen, glandular cells in the stomach and thyroid gland and squamous epithelial cells in the tonsil. We were unable to detect CD357 / GITR / TNFRSF18 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD357 / GITR / TNFRSF18 expression as measured by anti-CD357 / GITR / TNFRSF18 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | + | – | + | + | – | – | + | – | – | ++ | – | – | + | – | – | – | – | – | – | – |
| TNFRSF18 Variability | ++ | ++ | ++ | ++ | ++ | + | + | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | + | ++ | + | ++ | ++ |
| CD357 / GITR / TNFRSF18 General Information | |
|---|---|
| Alternate Names | |
| GITR, TNFRSF18, AITR, GITR-D, GITR, CD357 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | Tnfrsf18 |
| Entrez Gene ID | 21936 |
| Ensemble Gene ID | ENSMUSG00000041954 |
| RefSeq Protein Accession(s) | XP_017175602, NP_068820, NP_033426 |
| RefSeq mRNA Accession(s) | NM_021985, NM_009400, XM_017320113 |
| RefSeq Genomic Accession(s) | NC_000070 |
| UniProt ID(s) | Q540M6, O35714 |
| UniGene ID(s) | Q540M6, O35714 |
| Cosmic ID(s) | Tnfrsf18 |
| KEGG Gene ID(s) | mmu:21936 |
| General Description of CD357 / GITR / TNFRSF18. | |
| The DTA-1 antibody reacts with mouse CD357, also known as GITR or AITR (in humans), a 66-70 kDa member of the Tumor Necrosis Factor superfamily (TNFRSF18). GITR is primarily found on T cells, and its function may vary depending on the T cell type where it is expressed. GITR is upregulated on activated T cells where it provides co-stimulation, yet GITR may promote the inhibition of CD4+ CD25+ Treg cells, where it is expressed at high levels. GITR ligand (GITRL) is found on B cells, macrophages, dendritic and endothelial cells, and is implicated in regulating both innate and adaptive immune responses.The DTA-1 antibody may be used for analysis of GITR expression on T cells, and is also commonly used in vitro as an agonistic antibody to induce GITR signaling in various assays (use format appropriate for functional assays). | |
There are no reviews yet.